Table 5 Efficacy results in patients treated with lumiracoxib and rofecoxib (ITT population)
| Â | Week 3 | Week 6 | ||
|---|---|---|---|---|
Efficacy measures | Lumiracoxib 400 mg od ( n = 154) | Rofecoxib 25 mg od ( n = 155) | Lumiracoxib 400 mg od ( n = 154) | Rofecoxib 25 mg od ( n = 155) |
Patient's pain intensity | Â | Â | Â | Â |
   Improved n (%) | 53 (34.4) | 50 (32.3) | 49 (31.8) | 63 (40.6) |
   Non-improved n (%) | 101 (65.6) | 105 (67.7) | 105 (68.2) | 92 (59.4) |
Patient's global assessment of disease activity | Â | Â | Â | Â |
   Improved n (%) | 49 (31.8) | 53 (34.2) | 57 (37.0) | 65 (41.9) |
   Non-improved n (%) | 105 (68.2) | 102 (65.8) | 97 (63.0) | 90 (58.1) |
Physician's global assessment of disease activity | Â | Â | Â | Â |
   Improved n (%) | 44 (28.6) | 46 (29.7) | 51 (33.1) | 56 (36.1) |
   Non-improved n (%) | 110 (71.4) | 109 (70.3) | 103 (66.9) | 99 (63.9) |